Mark Bear is Picower Professor of Neuroscience at the Picower Institute for Learning and Memory at the Massachusetts Institute of Technology.
Mark Bear
Professor
Massachusetts Institute of Technology
Explore more from The Transmitter
Exclusive: Autism researchers ‘pleasantly surprised’ by list of NIH data project grantees, despite initial concerns
An atypical funding mechanism, truncated application timeline and opaque review process had generated concern over the quality of projects that would be selected for the Autism Data Science Initiative.
Exclusive: Autism researchers ‘pleasantly surprised’ by list of NIH data project grantees, despite initial concerns
An atypical funding mechanism, truncated application timeline and opaque review process had generated concern over the quality of projects that would be selected for the Autism Data Science Initiative.
By
Calli McMurray
2 October 2025 | 10 min read
Exclusive: Who is Richard Frye, the neurologist who researches and advocates for leucovorin as an autism treatment?
Frye has led two placebo-controlled trials of the folate supplement in autistic people; the first was suspended by regulators, and the other has yet to be published.
Exclusive: Who is Richard Frye, the neurologist who researches and advocates for leucovorin as an autism treatment?
Frye has led two placebo-controlled trials of the folate supplement in autistic people; the first was suspended by regulators, and the other has yet to be published.
By
Brendan Borrell
1 October 2025 | 11 min read
Why we need basic science to better understand the neurobiology of psychedelics
Despite the many psychedelics clinical trials underway, there is still much we don’t know about how these drugs work. Preclinical studies represent our best viable avenue to answer these lingering questions.
Why we need basic science to better understand the neurobiology of psychedelics
Despite the many psychedelics clinical trials underway, there is still much we don’t know about how these drugs work. Preclinical studies represent our best viable avenue to answer these lingering questions.
By
Devin Effinger, Melissa Herman
1 October 2025 | 7 min listen